SCIENTIFIC PROGRAMME
|
|
|
- Allan Simon
- 5 years ago
- Views:
Transcription
1 SCIENTIFIC PROGRAMME Tuesday, May 25 th ORAL PRESENTATIONS (HALL 1) Chairpersons : G. Baltagiannis, E. Vezali Oral Presentations HALL 2) Chairpersons: E. Dimou, O. Giouleme SYMPOSIUM (HALL 1) DECOMPENSATED CIRRHOSIS Chairpersons: K. Thomopoulos, A. Alexopoulou B- Blockers C. Triantos Optimal management as outpatient M. Mela Discussion BREAK / e-posters VIEWING ROUND TABLE (HALL 1) Complications of portal hypertension Chairpersons: K. Mimidis, S. Michopoulos Hepatic encephalopathy: Current and future treatment M. Deutsch Optimal treatment of varicose veins / variceal bleeding D. Samonakis Automatic bacterial peritonitis: Current views Ν. Papadopoulos Hepatorenal syndrome G. Kalampokis Discussion
2 ROUND TABLE (HALL 1) Research activities supported by HASL Chairpersons : J. Koskinas, G.N. Dalekos, G. Papatheodoridis BREAK / e-posters PRESENTATION Chairpersons 1 :K. Kaligeros, E. Thalassinos Chairpersons 2: D. Kountouras, A. Bellou Chairpersons 3: M. Deutsch, E. G ROUND TABLE (HALL 1) LIVER PARTICIPATION IN AUTOIMMUNE AND AUTOINFLAMMATORY LIVER DISEASES Chairpersons: G. N. Dalekos, K. Ritis Sarcoidosis M. Schina Antiphospholipid syndrome P. Vlachogiannopoulos Rheumatoid arthritis and adult Still s disease to adults D. Vasillopoulos Vasculitis Th. Dimitroulas Familial Mediterranean fever P. Skendros Discussion ROUND TABLE (HALL 2) PATIENTS MANAGEMENT BEFORE AND AFTER TRANSPLANTATION Chairpersons: E. Manesis, V. Papanicolaou Patient with NASH or alcoholic disease Ε. Τsochatzis Patient with chronic HBV or HCV infection Ε. Cholongitas Patient with hepatocellular carcinoma Ε. Sinakos Discussion
3 SYMPOSIUM (HALL 1) INFRINGEMENT OF LUNG IN CIRRHOSIS: CURRENT VIEWS Chairpersons: G. Hatzis, D. Christodoulou Porto-pulmonary hypertension Κ. Mimidis Hepatopulmonary syndrome D. Karagiannakis Discussion SYMPOSIUM ( HALL 2) Liver and coagulation abnormalities Chairpersons: D. Tsantoulas, J. Ketikoglou Clinical impact of coagulation rebalance in cirrhosis Ε. Rigopoulou Coagulation abnormalities in liver surgery Μ. Voulgarelis Discussion BREAK/ e-posters VIEWING SATELLITE SYMPOSIUM (HALL 1) OPENING CEREMONY (HALL 1) LECTURE L. Chatziagellakis Reception Gala Larissa Imperial Hotel
4 FRIDAY, May 26 th MEETING THE EXPERTS (HALL 1) Chairman : G. N. Dalekos Traps in the diagnosis of autoimmune hepatitis Ν. Gatselis MEETING THE EXPERTS (HALL 2) Chairman : S. Dourakis Diagnostic approach of solitary liver nodule Μ. Vlichou ORAL PRESENTATIONS (HALL 1) Chairpersons: S. Koutsounas, K. Patsiaoura ORAL PRESENTATIONS (HALL 2) Chairpersons: N. Tassopoulos, A. Protopapas STATE OF THE ART LECTURE (HALL 1) Chairman : K. Makaritsis Hyponatriemia in patients with liver diseases irrespectively of reduction in intravascular effective volume G. Liamis STATE OF THE ART LECTURE (HALL 2) Chairman : S. Karatapanis Clinical significance of gut microbiome in NAFLD/NASH Κ. Triantafillou BREAK/ e-posters VIEWING PLENNARY SESSION (HALL 1) Chairpersons:G.N. Dalekos, G. Papathoedoridis STATE OF THE ART LECTURE (HALL 1) Chairman : Α. Hatzakis HBV eradication: myth or reality S. Hadziyiannis SATELLITE SYMPOSIUM (HALL 1)
5 BREAK / e-posters PRESENTATION Chairpersons 1: M. Schina, N. Nikolaou Chairpersons 2: Ε. Sinakos, D. Samonakis Chairpersons 3: G. Kalampokis, E. Dimou ROUND TABLE (HALL 1) CHRONIC HEPATITIS B Chairpersons: C. Gogos, J. Koskinas The role of HΒsAg and HBcrAg E. Hadziyanni HBV reactivation under immunosuppression Α. Αlexopoulou Hepatocellular carcinoma prevention S. Manolakopoulos Discussion ROUND TABLE (HALL 2) ALMOST RARE LIVER DISEASES Chairpersons: Th. Vasileiadis, I. Elefsiniotis Developments in epidemiology and treatment of HDV and HEV Ν. Gatselis Current views in primary biliary cholangitis (PBC) Ι. Pachiadakis Heridetary liver diseases in adults V. Sevastianos Discussion BREAK/ e-posters VIEWING ROUND TABLE (HALL 1) HEPATOCELLULAR CARCINOMA Chairpersons: E. Kouroumalis, E. Tsianos Indications and surveillance methods I. Rapti Optimal interstage treatment V. Papadimitropoulos New treatments G. Germanidis Discussion
6 SYMPOSIUM (HALL 2) ALCOHOLIC LIVER DISEASE Chairpersons: S. Karatapanis, Ch. Drakoulis Alcoholic hepatitis : modern treatment Ι. Elefsiniotis Practical approaches in treatment of malnutrition and addiction Μ. Κoulentaki Discussion SATELLITE SYMPOSIUM (HALL 1) SATURDAY, May 27 th SEMINAR (HALL 1) CURRENT ISSUES IN CLINICAL HEPATOLOGY PART 1 Chairpersons: Ε. Akriviadis, E. Cholongitas Drug hepatotoxicity S. Dourakis Antivirals stop in chronic hepatitis B: When and to whom? G. Papatheodoridis Drug treatment in NASH : Present and future Ε. Τsochatzis Discussion PART 2 Chairpersons: G. Koukoulis, I. Fezoulidis Contribution of radiodiagnostic in modern treatment and monitoring of hepatic disease V. Georgopoulou The role of liver biopsy in modern clinical practice P. Hytiroglou Discussion BREAK/ e-posters VIEWING
7 ROUND TABLE (HALL 1) NEW CHALLENGES IN AUTOIMMUNE LIVER DISEASES Chairpersons: G.N. Dalekos, A.W. Lohse Further diagnostic considerations in autoimmune hepatitis (AIH) G.N. Dalekos Emerging new therapies in primary biliary cholangitis (PBC) O. Chazouilleres AIH/PBC and AIH/PSC variants: Reality or a myth? A.W. Lohse Comments - Discussion ROUND TABLE (HALL 2) Contribution of histopathology and surgery in therapeutic manipulation of liver masslesions Chairpersons: K. Tepetes, J. Delladetsima The role of the pathologist D. Tiniakos Surgical treatment of benign liver tumors G. Sotiropoulos Surgical treatment of cholangiocarcinoma Ε. Felekouras Surgical treatment of liver metastases: When and to whom? G. Gklatzounis Discussion SATELLITE SYMPOSIUM (HALL 1) BREAK/ e-posters VIEWING Chairpersons 1: A. Kapatais, I. Rapti Chairpersons 2 : I. Rigopoulou, C. Mandros Chairpersons 3 : A. Hounta, S. Gampeta HASL s Members Meeting STATE OF THE ART LECTURE (HALL 1) Chairperson : I. Vafiadi Non-cirrhotic portal hypertension J. Koskinas
8 STATE OF THE ART LECTURE (HALL 2) Chairperson : Ε. Antoniou Bariatric surgery in NAFLD / NASH G. Tzovaras BREAK/ e-posters VIEWING SATELLITE SYMPOSIUM (HALL 1) ROUND TABLE (HALL 1) CHRONIC HEPATITIS C : 2017 Chairpersons: G. Papatheodoridis, A. Hatzakis Therapeutic intervention guidelines Ι. Goulis DAAs and recurrence or development of HCC J. Vlachogiannakos DAAs in patients who inject intravenous drugs: access for all? V. Sypsa Discussion Conclusions of the Conference G. N. Dalekos, G. Papatheodoridis CLOSING CEREMONY 21:30 Gala Dinner En Larissi Restaurant
PROGRAMME AT A GLANCE
PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver
16th Panhellenic IBD Congress June 9th -11th, 2017 Amalia Hotel in Nafplion, Greece
16th Panhellenic IBD Congress June 9th -11th, 2017 Amalia Hotel in Nafplion, Greece Scientific Programme Friday, June 9 th 2017 08.00 09.30 Video presentations 09.30 11.00 Video presentations 11.00 11.30
DACLATASVIR: Update on new data from the real world over the past year. Dr M. MELA EVANGELISMOS GENERAL HOSPITAL
1392GR1700862-01 3/2017 1392GR1700862-01 3/2017 DACLATASVIR: Update on new data from the real world over the past year Dr M. MELA EVANGELISMOS GENERAL HOSPITAL 9 th International Congress of Internal Medicine
Transplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
George Papatheodoridis. Developing a national plan: Greece
George Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National and Kapodistrian University of Athens, Member of the Committee of the Hellenic National Plan for Hepatitis C,
Background. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012)
Interferon-induced protein 10 (IP10) at discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy cannot predict subsequent relapses in non-cirrhotic HBeAgnegative chronic hepatitis B (CHBe-)
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.
Investigations before OLT, Immunosuppression and rejection, Follow up after OLT andrea.degottardi@insel.ch When is liver transplantation indicated? When is liver transplantation indicated? Frequent: CIRRHOSIS
GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE
GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE Kalliopi Azariadis 1, Nikolaos K. Gatselis 1, Kalliopi Zachou 1, Vasiliki Lygoura 1, Pinelopi Arvaniti 1, Eirini I. Rigopoulou 1, Georgia
4th UpDate on Hepatology
4th UpDate on Hepatology Course Bucharest 2017, Romania 6 th - 7 th April 2017 Bucharest - Crowne Plaza Hotel Hepatology 2017 A panoramic view" Liana GHEORGHE Course Directors Ioan SPOREA Anca TRIFAN 4
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt
The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom
The Sheila Sherlock Royal Free Hepatology Postgraduate Course 2019 Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom *Includes histopathology within talk # Includes radiology
Ontario s Adult Referral and Listing Criteria for Liver Transplantation
Ontario s Adult Referral and Listing Criteria for Liver Transplantation Version 3.0 Trillium Gift of Life Network Ontario s Adult Referral & Listing Criteria for Liver Transplantation PATIENT REFERRAL
Life After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
Tumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York
Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:
FRIDAY, MARCH 9 SUNDAY, MARCH
33RD A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 9 SUNDAY, MARCH 11, 2018 Pre-Conference: Friday, March 9, 2018 Main Conference: Saturday, March 10-11, 2018 Estancia La Jolla Course
Hepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
Epidemiology of hepatitis B and D in Greece
Epidemiology of hepatitis B and D in Greece George V. Papatheodoridis Assistant Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration
Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
Liver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
FRIDAY, MARCH 31 SUNDAY, APRIL
32ND A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 31 SUNDAY, APRIL 2, 2017 Pre-Conference: Friday, March 31, 2017 Main Conference: Saturday, April 1-2, 2017 Estancia La Jolla La Jolla,
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition SIXTH DRAFT OF THE PROGRAM AUGUST 28, 2014 Wednesday, October 5, 2016 08:00-16:30 Post Graduate course (To be developed by the
The 10th Congress of the Jordanian Society of Gastroenterology & Hepatology
2014 The 10th Congress of the Jordanian Society of Gastroenterology & Hepatology Organized by: The Jordanian Society of Gastroenterology & Hepatology In Collaboration with: The Pan Arab Society of Gastroenterology
Supplementary Digital Content
Geissler et al: Sirolimus and Hepatocellular Carcinoma in Liver Transplantation Page 1 of 10 Supplementary Digital Content Supplementary Table 1. Surgical procedures used Total Transplant technique Piggy
Liver Failure. The most severe clinical consequence of liver disease is liver failure:
Liver diseases I The major primary diseases of the liver are: - Viral hepatitis, - Nonalcoholic fatty liver disease (NAFLD), - Alcoholic liver disease, - Hepatocellular carcinoma (HCC) Hepatic damage also
Entrustable Professional Activity
Entrustable Professional Activity 1. EPA Title: Care of infants, children and adolescents with acute and chronic s 2. Description of Activity Practicing subspecialists must be trained to care for children
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty
End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
34TH. New Treatments in Chronic Liver Disease. MAIN CONFERENCE: MARCH 9 10, 2019 Pre-Conference: March 8, 2019 Estancia La Jolla La Jolla, California
34TH A N N U A L New Treatments in Chronic Liver Disease MAIN CONFERENCE: MARCH 9 10, 2019 Pre-Conference: March 8, 2019 Estancia La Jolla Course Introduction Course Overview This CME conference will review
Liver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols
Overall Goals and Objectives for Transplant Hepatology EPAs:
Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills
Hepatitis B: Who and when to treat?
Received: 7 November 2017 Accepted: 8 November 2017 DOI: 10.1111/liv.13631 REVIEW ARTICLE Hepatitis B: Who and when to treat? Jiannis Vlachogiannakos George V. Papatheodoridis Department of Gastroenterology,
Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
NEURO- GASTRO- ENTEROLOGY & MOTILITY OESO- PHAGUS LOGY. Room A Room B Room C Room E1 Room E2 Room M Room N1 Room N2 Room L8 Room 1.
ONCO ENTERO RADIO & SATURDAY SUNDAY MONDAY TUESDAY WEDNESDAY Saturday, October 15, 2016 Room A Room B Room C Room E1 09:00-10:30 Peptic ulcer : Still important for gastroenterologists 11:00-13:00 Video
Hepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
Detection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
The future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
Causes of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
Cirrhosis is different from Fibrosis
Riunione Monotematica AISF 2016 «The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist» Milan 13 th -14 th 2016 Cirrhosis is different from Fibrosis I have not disclosures to declare
The Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Hepatology Director and Medical Director of Liver Transplantation Intermountain Medical Center Salt Lake City, Utah FORMATTED: 05-14-15
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
LIVER DISEASE WRAP-UP
20th Annual LIVER DISEASE WRAP-UP An Update on Advances in Clinical Hepatology An update on advances in clinical hepatology presented at the 2017 AASLD Meeting for Practicing Internists, Gastroenterologists,
Hepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs
PROFESSIONAL ISSUES Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs Simon Whalley, Prasanthi Puvanachandra, Atman Desai and Hugh Kennedy
World Health Organization. Western Pacific Region
Basic modules for hepatitis 1 Basic Module 1 Liver anatomy and physiology 2 Position of liver Midline Located in right upper abdomen Protected by the right rib cage Right upper Measures: 12 15 cm in vertical
Research in Hepatology What is hot and what is not!
Research in Hepatology What is hot and what is not! Anna SF Lok, MD University of Michigan Ann Arbor, MI, USA Please consider the environment before printing this PowerPoint Outline How to define hot?
AASLD, Boston, USA, 10 th November 2014 [oral presentation]
![AASLD, Boston, USA, 10 th November 2014 [oral presentation]](/thumbs/89/98795522.jpg "AASLD, Boston, USA, 10 th November 2014 [oral presentation]")
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
Hepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
with cirrhosis should remain under HCC surveillance
Hepatology Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine
Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1
Supplemental Tables Supplemental Table 1 Various etiologies of liver cirrhosis and their association with liver stiffness and AST/ALT ratio Disease category Cause Example LS AST/ALT Inflammatory liver
Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006
Vt-2006 The pathology of the liver, bile ducts and pancreas Richard Palmqvist Docent, ST-läkare, Klin Pat Lab, Labcentrum The lecture in summary Introduction, histology & physiology in brief General phenomenon
During the course of the 12 month fellowship, candidates will attend at least one international liver meeting (generally AASLD).
Hepatology and Liver Transplantation fellowship Length: 1 year Number of positions: 2 Type of fellowship: Clinical and Research Fellowship Director: Dr. Deschenes McGill University Health Centre Fellowship
King Abdul-Aziz University Hospital (KAUH) is a tertiary
Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors
Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
Liver disease in 2017: challenges and opportunities
Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
HEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
ASSESSMENT AND MANAGEMENT OF POTENTIAL LIVER TRANSPLANT CANDIDATES
ASSESSMENT AND MANAGEMENT OF POTENTIAL LIVER TRANSPLANT CANDIDATES James YY Fung MBChB, MD, FRACP, FHKCP, FHKAM Consultant & Hon. Assoc. Professor Liver Transplant Center Department of Surgery, Queen Mary
PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
What s new in Hepatology AASLD 2016
What s new in Hepatology AASLD 2016 CWN Spearman C Kassianides What s new in Hepatology? AASLD 2016 CWN SPEARMAN Hepatitis C Alcoholic liver disease Cholestatic Liver Disease Primary biliary Cholangitis
Changing epidemiology of HCC in Italy
Changing epidemiology of HCC in Italy G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche-Trapianto di Fegato Università Politecnica delle Marche, Ancona Worldwide estimated new PLC
Hepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
MINI PROGRAMME SEE YOU NEXT YEAR IN LONDON APRIL 2020
MINI PROGRAMME WWW.ILC-CONGRESS.EU SEE YOU NEXT YEAR IN LONDON 15-19 APRIL 2020 Registration area Foyer D Membership fast-track, self-registration lanes, help desk, accommodation desk, congress material,
DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.
DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC. Robert J. de Knegt, Erasmus MC, Rotterdam r.deknegt@erasmusmc.nl Disclosures
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes
ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman.
ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman. to change at any time www.arlar.org info@arlar.org #ArLAR2018 Thursday, 22
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acalculous cholecystitis, postoperative, 190 191 Acute cardiac failure, hypoxic liver injury and, in critically ill and postoperative patients,
Hepatitis B (and D) Cure Strategies: How far are we?
Hepatitis B (and D) Cure Strategies: How far are we? Heiner Wedemeyer Dept. of Gastroenterology and Hepatology Essen University Hospital International Hepatitis E Symposium February 14-16, 2019 H. Wedemeyer
The Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Professor of Medicine University of Chicago Chicago, Illinois Overview Initial assessment of liver disease How do you diagnose cirrhosis?
DIAGNOSIS OF NASH LIVER BIOPSY. PHC
DIAGNOSIS OF NASH LIVER BIOPSY PHC 2018 - www.aphc.info 1 THE NATURAL HISTORY OF NAFLD STEATOSIS (NAFL) STEATOHEPATITIS (NASH) FIBROSIS CIRRHOSIS HCC UNDER THE LENS : THE 3 HISTOLOGICAL COMPONENTS OF NAFLD
HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS
HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS HEPAMAP: A Roadmap For Hepatology Research In Europe: An Overview For Policy Makers Liver diseases are extremely costly
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
Prevention of Viral Hepatitis in Greece: Lessons learnt and the way forward
Background document Prevention of Viral Hepatitis in Greece: Lessons learnt and the way forward Viral Hepatitis Prevention Board Meeting Athens, Greece, November 15-16, 2007 Alex Vorsters VHPB Secretariat
Clinical and epidemiological characteristics of hepatitis C virusinfected people who inject drugs: a Greek descriptive analysis
ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 1-6 Clinical and epidemiological characteristics of hepatitis C virusinfected people who inject drugs: a Greek descriptive analysis Hariklia Kranidioti
BASL Annual Meeting Programme BASIC SCIENCE SYMPOSIUM UNDERSTANDING AND HARNESSING VIRAL RESISTANCE Chairs: Matthew Cramp
BASL Annual Meeting Programme BASIC SCIENCE SYMPOSIUM UNDERSTANDING AND HARNESSING VIRAL RESISTANCE Chairs: Matthew Cramp WEDNESDAY 19 th September 2018 09:30 09:55 09:55 10:20 10:20 10:45 The HBV and
Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax
Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus 231-727-5575/231-728-4054 Fax » CURABLE» Most common blood borne infection» 75-85% of those exposed will develop chronic infection»
Treatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
Hepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH
Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated
Module 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
Autoimmune Hepatitis Events Easl
Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating
B C Outlines. Child-Pugh scores
B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging
Autoimmune Liver Diseases
2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
Scientific Program Venue: Le Meridien Hotel Amman October The 3 rd International Congress of the Jordanian Rheumatism Society (JRS)
2014 The 3 rd International Congress of the Jordanian Rheumatism Society (JRS) Organized by: Jordanian Rheumatism Society (JRS) In Collaboration with: British Society for Rheumatology (BSR) Scientific
Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
BREAKS NETWORKING EVENTS PARALLEL SESSIONS INDUSTRY SUPPORTED SESSIONS Academy of Autoimmunity SYMPOSIUM
PLENARY SESSIONS BREAKS NETWORKING EVENTS PARALLEL SESSIONS INDUSTRY SUPPORTED SESSIONS SYMPOSIUM Monday, 14 May 2018 13:00-15:30 15:30 16:00 COFFEE BREAK 16:00-17:30 Tuesday, 15 May 2018 08:00-08:30 08:30-10:30
MRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA
MRI for HCC surveillance and reporting: LI-RADS Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA Cirrhotic Nodules Regenerative Nodule Atypical Nodule Hyperplastic Nodule Dysplastic